NCT06595563
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06595563
Title HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer (ZEPHIR-02)
Acronym ZEPHIR-02
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Jules Bordet Institute
Indications
Therapies
Age Groups: senior | adult
Covered Countries BEL

Facility Status City State Zip Country Details
Institut Jules Bordet RECRUITING Anderlecht Brussels Capital 1070 Belgium Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field